Revive Therapeutics Ltd. (31R)
XFRA 
Summary
31R Chart
Revive Therapeutics Ltd. (31R) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revive Therapeutics Ltd. ever had a stock split?
Revive Therapeutics Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Michael Frank CEO | XFRA Exchange | CA7615161030 ISIN |
| CA Country | 3 Employees | - Last Dividend | 25 Jan 2017 Last Split | - IPO Date |
Overview
Revive Therapeutics Ltd. is a life sciences company that dedicates its efforts to the research and development of therapeutics aimed at rare disorders and infectious diseases. The company's core focus is on a diverse cannabinoid pharmaceutical portfolio designed to target rare inflammatory diseases. In addition, Revive Therapeutics is actively pursuing innovative treatments across a variety of medical conditions, including infectious diseases like influenza and COVID-19, as well as mental health disorders and autoimmune diseases. Based in Toronto, Canada, Revive is at the forefront of developing groundbreaking therapies that aim to address unmet medical needs in various patient populations around the world.
Products and Services
- Bucillamine
- Psilocybin
- Psilocin
- Cannabidiol
Currently in Phase 3 clinical study, Bucillamine is being developed as a potential treatment for infectious diseases, such as influenza and COVID-19. This development stage reflects Revive's commitment to addressing the urgent need for effective treatments against current and emerging infectious diseases.
Undergoing a Phase 1 clinical study, Psilocybin represents Revive's foray into addressing psychological and dependency disorders, specifically targeting methamphetamine use disorder. This research underscores the company's dedication to exploring innovative therapeutic avenues for addiction treatment.
Psilocin is being investigated for its potential in treating a wide range of mental health conditions, including depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other diseases. This exploration signifies the company's commitment to leveraging psychedelic compounds for the betterment of mental health therapies.
Part of Revive's cannabinoid portfolio, Cannabidiol (CBD) is aimed at treating autoimmune hepatitis and ischemia and reperfusion injury resulting from organ transplantation. This initiative demonstrates the company’s effort in utilizing cannabinoids beyond their traditional uses, targeting severe health conditions with significant patient impact.
